<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Digoxin: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Digoxin: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Digoxin: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12382" href="/d/html/12382.html" rel="external">see "Digoxin: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="13230" href="/d/html/13230.html" rel="external">see "Digoxin: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F160142"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Digitek [DSC];</li>
<li>Digox [DSC];</li>
<li>Lanoxin;</li>
<li>Lanoxin Pediatric</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52866593"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>JAMP-Digoxin;</li>
<li>Lanoxin [DSC];</li>
<li>PMS-Digoxin</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F160189"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antiarrhythmic Agent, Miscellaneous;</li>
<li>
                        Cardiac Glycoside</li></ul></div>
<div class="block doa drugH1Div" id="F160147"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Safety:</b> Toxicity may occur even at therapeutic concentrations in some settings (eg, hypokalemia). Periodically monitor digoxin concentrations as appropriate for the condition being treated, especially if kidney impairment occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> When changing from oral (tablets or liquid) to IV therapy, reduce dosage by 20% to 25%.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="0156d4e3-c53d-4d3c-809d-02d27775d840">Atrial fibrillation/flutter, rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation/flutter, rate control (alternative agent): Note:</b> Some experts reserve digoxin for patients whose rate has not adequately been controlled with other agents or interventions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Giardina.2018','lexi-content-ref-Ganz.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Giardina.2018','lexi-content-ref-Ganz.2018'])">Ref</a></span>). Additionally, digoxin is not effective for rate control during high-adrenergic states (eg, exercise); a beta-blocker is preferred. Do <b>not</b> use in patients with preexcitation associated with an accessory pathway, as this can lead to ventricular arrhythmias (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total digitalizing dose (TDD):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>May initiate with a loading dose followed by maintenance dosing if rapid titration is desired or initiate with maintenance dosing without a loading dose.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral/IV:</b> 0.25 to 0.5 mg once; repeat doses of 0.25 mg every 6 hours to a maximum of 1.5 mg over 24 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347','lexi-content-ref-Giardina.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347','lexi-content-ref-Giardina.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>or</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral/IV:</b> 8 to 12 mcg/kg (use lean body weight; not to exceed 0.75 to 1.5 <b>mg</b> over 24 hours); administer by giving 50% of TDD once, then administer the remaining 50% as 2 doses of 25% of TDD at 4- to 8-hour intervals; round doses to standard amounts (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20956224','lexi-content-ref-Giardina.2018','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20956224','lexi-content-ref-Giardina.2018','lexi-content-ref-Manu.1'])">Ref</a></span>). For example, TDD of 12 <b>mcg</b>/kg in an 80 kg patient by lean body weight = 960 <b>mcg</b>. Administer 0.5 <b>mg</b> once, then 0.25 <b>mg</b> every 6 hours for 2 doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dose:</i>
<b>Oral:</b> 0.125 to 0.25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24682347']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24682347'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ab2992d0-fd54-48ab-ae38-f9e9ac7b9a6e">Fetal supraventricular tachyarrhythmia, sustained</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fetal<b> supraventricular tachyarrhythmia</b>, sustained (maternal administration for transplacental transfer to the fetus) (off-label use): Note:</b> These patients should be managed by a highly experienced fetal arrhythmia team. Due to decreased placental transfer, maternal administration of digoxin may be less effective when fetal hydrops is present (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24763516','lexi-content-ref-29246961','lexi-content-ref-21931080','lexi-content-ref-Levine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24763516','lexi-content-ref-29246961','lexi-content-ref-21931080','lexi-content-ref-Levine.1'])">Ref</a></span>). The lowest effective dose should be used to avoid maternal adverse events (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29208503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29208503'])">Ref</a></span>). Prior to use, evaluate appropriateness of therapy to the mother (eg, maternal electrolytes, kidney function, ECG).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Maternal dose:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose (may be given oral or IV):</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>IV:</b> 1.2 to 1.5 mg over 24 hours given in divided doses every 8 hours; follow with oral maintenance regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24763516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24763516'])">Ref</a></span>). Some experts do not recommend IV administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Levine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Levine.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 1 to 2 mg given over 24 to 48 hours in divided doses (eg, 0.5 mg followed by 0.25 mg, then 0.25 mg over the first 18 to 24 hours with subsequent additional doses as needed to achieve target levels); follow with an oral maintenance regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29246961','lexi-content-ref-21931080','lexi-content-ref-Levine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29246961','lexi-content-ref-21931080','lexi-content-ref-Levine.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>Oral:</b> 0.375 mg to 0.75 mg per day given in divided doses every 8 to 12 hours. Adjust dose to maintain a target maternal blood level between 0.7 and 2 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24763516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24763516'])">Ref</a></span>). Some experts recommend dividing into 3 times daily dosing to ensure adequate drug levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Levine.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Levine.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b43376ec-cceb-40f9-ad1e-9137f312af09">Heart failure with reduced ejection fraction</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction: Note: </b>Reserve for use in patients with persistent New York Heart Association functional class III or IV symptoms despite optimal guideline-directed medical therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dose</i> (loading dose not recommended): <b>Oral:</b> 0.125 to 0.25 mg once daily; target a serum digoxin concentration of 0.5 to &lt;0.9 ng/mL; higher daily doses are rarely necessary. If patient is &gt;70 years of age, has impaired kidney function, or has a low lean body mass, low doses (eg, 0.125 mg daily or every other day) should be used initially (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>). A dosing nomogram is also available based on lean body weight and CrCl (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25164709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25164709'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c50d4c0f-58c9-4fd1-bef2-23f754f16693">Supraventricular tachycardia, rate control</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia), rate control (alternative agent) (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Total digitalizing dose:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Initial: 0.5 mg loading dose, with additional 0.125 to 0.25 mg doses administered at 6- to 8-hour intervals until evidence of adequate effect (maximum total dose over 24 hours: 8 to 12 <b>mcg</b>/kg [use lean body weight], not to exceed 0.75 to 1.5 <b>mg</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259','lexi-content-ref-Giardina.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259','lexi-content-ref-Giardina.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV:</b> Initial: 0.25 to 0.5 mg loading dose, with additional 0.25 mg doses administered at 6- to 8-hour intervals until evidence of adequate effect (maximum total dose over 24 hours: 8 to 12 <b>mcg</b>/kg [use lean body weight], not to exceed 0.75 to 1.5 <b>mg</b>) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259','lexi-content-ref-Giardina.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259','lexi-content-ref-Giardina.2018'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance dose: </i>
<b>Oral:</b> 0.125 to 0.25 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26409259']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26409259'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990804"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Periodically monitor digoxin concentrations as appropriate for the condition being treated. Toxicity may occur even at therapeutic concentrations in some settings (eg, hypokalemia).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atrial fibrillation/flutter, supraventricular tachycardia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>IV, Oral:</b></p>
<p style="text-indent:-2em;margin-left:8em;">Loading dose: <b>Note:</b> Use with caution and only when rapid ventricular rate control is necessary.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &gt;15 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl ≤15 mL/minute: Administer 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9165563','lexi-content-ref-7461014','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9165563','lexi-content-ref-7461014','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Maintenance dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">
<b>Note:</b> Patients with low lean body weight may require lower doses. Doses of 0.0625 mg once daily may be given as 0.125 mg every other day.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl ≥60 mL/minute: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl 45 to &lt;60 mL/minute: 0.0625 to 0.125 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl 30 to &lt;45 mL/minute: 0.0625 mg once daily.</p>
<p style="text-indent:-2em;margin-left:10em;">CrCl &lt;30 mL/minute: 0.0625 mg every 48 hours or consider alternative agent.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart failure:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b></p>
<table border="1" frame="border" rules="all" style="margin-left:4em;">
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" colspan="3">
<p style="text-indent:0em;">Digoxin Dosing Suggestions When Used for Heart Failure<sup class="footnote-number">a,b</sup></p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">
<b>Ideal</b> body weight (kg)</p></th>
<th align="center">
<p style="text-indent:0em;">CrCl (mL/minute)</p></th>
<th align="center">
<p style="text-indent:0em;">Digoxin dose</p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;text-align:left;">
<sup>a</sup>Derived from a contemporary digoxin dosing nomogram using CrCl and ideal body weight or height for determining the initial maintenance dose in patients with heart failure to achieve a target digoxin concentration of 0.7 ng/mL (Bauman 2006, DiDomenico 2014).</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>b</sup>No loading dose necessary.</p></td></tr>
<tr>
<td align="left" colspan="3" valign="middle">
<p style="text-indent:0em;">
<sup>c</sup>May administer as 0.125 mg every other day.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">45 to 50</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;60</p></td>
<td align="center">
<p style="text-indent:0em;">0.125 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 60</p></td>
<td align="center">
<p style="text-indent:0em;">0.0625 mg once daily<sup class="footnote-number">c</sup></p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">&gt;50 to 60</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;110</p></td>
<td align="center">
<p style="text-indent:0em;">0.25 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;45 to 110</p></td>
<td align="center">
<p style="text-indent:0em;">0.125 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 45</p></td>
<td align="center">
<p style="text-indent:0em;">0.0625 mg once daily<sup class="footnote-number">c</sup></p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">&gt;60 to 70</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;110</p></td>
<td align="center">
<p style="text-indent:0em;">0.25 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;35 to 110</p></td>
<td align="center">
<p style="text-indent:0em;">0.125 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 35</p></td>
<td align="center">
<p style="text-indent:0em;">0.0625 mg once daily<sup class="footnote-number">c</sup></p></td></tr>
<tr>
<td align="center" rowspan="3">
<p style="text-indent:0em;">&gt;70 to 80</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;80 to 110</p></td>
<td align="center">
<p style="text-indent:0em;">0.25 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;20 to 80</p></td>
<td align="center">
<p style="text-indent:0em;">0.125 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 20</p></td>
<td align="center">
<p style="text-indent:0em;">0.0625 mg once daily<sup class="footnote-number">c</sup></p></td></tr>
<tr>
<td align="center" rowspan="2">
<p style="text-indent:0em;">&gt;80</p></td>
<td align="center">
<p style="text-indent:0em;">&gt;70</p></td>
<td align="center">
<p style="text-indent:0em;">0.25 mg once daily</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">15 to 70</p></td>
<td align="center">
<p style="text-indent:0em;">0.125 mg once daily</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3052985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3052985'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use if possible; use in end-stage kidney disease is associated with increased mortality (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20576808']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20576808'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atrial fibrillation/flutter, supraventricular tachycardia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>Oral, IV:</b> Use with caution and<b> only</b> when rapid ventricular rate control is necessary. Reduce to 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9165563','lexi-content-ref-Foote.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9165563','lexi-content-ref-Foote.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>Oral, IV:</b> 0.0625 mg every 48 hours or 3 times/week may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart failure: </i>Maintenance dose: <b>Oral:</b> 0.0625 mg every 48 hours or 3 times/week may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25371716','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25371716','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3052985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3052985'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atrial fibrillation/flutter, supraventricular tachycardia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>Oral, IV: </b>Use with caution and<b> only</b> when rapid rate control is necessary. Reduce to 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Foote.1','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Foote.1','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>Oral, IV: </b>0.0625 mg every 48 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart failure:</i> Maintenance dose: <b>Oral: </b>0.0625 mg every 48 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Close monitoring of response, serum drug concentrations, and adverse reactions (eg, arrhythmias) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atrial fibrillation/flutter, supraventricular tachycardia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>Oral, IV: </b>Reduce to 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution and only when rapid rate control is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>Oral, IV: </b>0.0625 to 0.125 mg every 48 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24249760','lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24249760','lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart failure:</i> Maintenance dose: <b>Oral: </b>0.0625 to 0.125 mg every 48 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24249760','lexi-content-ref-Golightly.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24249760','lexi-content-ref-Golightly.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Drug clearance is dependent on the effluent flow rate, filter type, and method of renal replacement. Recommendations are based on high-flux dialyzers and effluent flow rates of 20 to 25 mL/kg/hour (or ~1,500 to 3,000 mL/hour) unless otherwise noted. Close monitoring of response, serum drug concentrations, and adverse reactions (eg, arrhythmias) due to drug accumulation is important.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Avoid use if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Atrial fibrillation/flutter, supraventricular tachycardia:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Loading dose: <b>Oral, IV: </b>Reduce to 50% of usual dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>). Use with caution and only when rapid rate control is necessary.</p>
<p style="text-indent:-2em;margin-left:6em;">Maintenance dose: <b>Oral, IV: </b>0.0625 to 0.125 mg every 48 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Heart failure:</i> Maintenance dose: <b>Oral: </b>0.0625 mg every 48 hours may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988003"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment necessary.</p></div>
<div class="block doe drugH1Div" id="F160148"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Dose is based on assessment of lean body mass and kidney function. Elderly patients with low lean body mass may experience higher digoxin concentrations due to reduced volume of distribution (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21335295']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21335295'])">Ref</a></span>). Decrease dose in patients with decreased kidney function (see Dosing: Altered Kidney Function).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation: </b>Avoid as first-line therapy; if used, do not exceed 0.125 mg/day in patients ≥65 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction:</b> If patient is &gt;70 years of age, low doses (eg, 0.125 mg daily or every other day) should be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35363499']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35363499'])">Ref</a></span>). Avoid as first-line therapy; if used, do not exceed 0.125 mg/day in patients ≥65 years of age. Use caution when discontinuing due to potential for clinical worsening (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-37139824']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-37139824'])">Ref</a></span>).</p></div>
<div class="block dop drugH1Div" id="F160169"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="13230" href="/d/html/13230.html" rel="external">see "Digoxin: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing: </b>Dosage must be individualized due to substantial individual variation and must take into account renal function. Doses should be based on lean body weight. When changing from oral solution to IV therapy, dosage should be reduced by 20% to 25%.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="86fd017b-f098-427e-b843-c16a24638f11">Heart failure</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure:</b> Injection, Oral: Infants, Children, and Adolescents: The dosage tables below list dosage recommendations for normal renal function and are based upon average patient response; lower doses are needed for patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Digitalizing dose, initial regimen (optional):</b> Total digitalizing dose should be divided (see below); digitalizing dose (loading dose) may not be necessary; consider use if rapid titration is desired. To avoid toxicity, consider doses at lower end of the recommended range; dosage should be individualized based on patient response (eg, clinical response, serum drug levels).</p>
<table border="1" frame="border" rules="all">
<caption>
<b>Dosage Recommendations for Digitalizing Dose<sup>A</sup> (Optional)</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Age</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Total Digitalizing Dose</p>
<p style="text-indent:0em;">Administer in 3 divided doses<sup>B</sup></p>
<p style="text-indent:0em;">(mcg/kg)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Oral Solution</p></th>
<th align="center">
<p style="text-indent:0em;">Tablets</p></th>
<th align="center">
<p style="text-indent:0em;">IV<sup>C</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>A</sup>Based on lean body weight and normal renal function for age.</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>B</sup>
<b>Do not give full total digitalizing dose (TDD) at once.</b> Give one-half of the TDD for the initial dose, then give one-quarter of the TDD for each of 2 subsequent doses at 6- to 8-hour intervals; prior to additional doses, clinical response should be fully evaluated (eg, ECG).</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>C</sup>May also be administered by IM; however, not recommended.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">1 to 24 months</p></td>
<td align="center">
<p style="text-indent:0em;">35 to 60</p></td>
<td align="center">
<p style="text-indent:0em;">−</p></td>
<td align="center">
<p style="text-indent:0em;">30 to 50</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 to 5 years</p></td>
<td align="center">
<p style="text-indent:0em;">30 to 45</p></td>
<td align="center">
<p style="text-indent:0em;">−</p></td>
<td align="center">
<p style="text-indent:0em;">25 to 35</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5 to 10 years</p></td>
<td align="center">
<p style="text-indent:0em;">20 to 35</p></td>
<td align="center">
<p style="text-indent:0em;">20 to 45</p></td>
<td align="center">
<p style="text-indent:0em;">15 to 30</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;10 years</p></td>
<td align="center">
<p style="text-indent:0em;">10 to 15</p></td>
<td align="center">
<p style="text-indent:0em;">10 to 15</p></td>
<td align="center">
<p style="text-indent:0em;">8 to 12</p></td></tr></tbody></table>
<table border="1" frame="border" rules="all">
<caption>
<b>Maintenance Dosage Recommendations for Digoxin<sup>A,B</sup></b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead valign="middle">
<tr>
<th align="center" rowspan="2">
<p style="text-indent:0em;">Age</p></th>
<th align="center" colspan="3">
<p style="text-indent:0em;">Daily Maintenance Dose</p>
<p style="text-indent:0em;">If ≤10 years, administer in equal divided doses twice daily</p>
<p style="text-indent:0em;">If &gt;10 years, administer once daily</p>
<p style="text-indent:0em;">(mcg/kg/day)</p></th></tr>
<tr>
<th align="center">
<p style="text-indent:0em;">Oral Solution</p></th>
<th align="center">
<p style="text-indent:0em;">Tablets</p></th>
<th align="center">
<p style="text-indent:0em;">IV<sup>C,D</sup></p></th></tr></thead>
<tfoot valign="middle">
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>A</sup>Dosing reflects clinical practice and in some cases, varies from manufacturer labeling (Bakir 1994; Bendayan 1983; Latifi 2000; Park 1986).</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>B</sup>Based on lean body weight and normal renal function for age. Decrease maintenance dose in patients with decreased renal function.</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>C</sup>May also be administered by IM; however, not recommended.</p></td></tr>
<tr>
<td align="left" colspan="4" valign="middle">
<p style="text-indent:0em;">
<sup>D</sup>Daily maintenance IV dose is typically 20% to 30% of total digitalizing IV dose in pediatric patients ≤24 months and 25% to 35% in older pediatric patients.</p></td></tr></tfoot>
<tbody valign="middle">
<tr>
<td align="center">
<p style="text-indent:0em;">1 to 24 months</p></td>
<td align="center">
<p style="text-indent:0em;">10 to 15</p></td>
<td align="center">
<p style="text-indent:0em;">−</p></td>
<td align="center">
<p style="text-indent:0em;">9 to 15</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">2 to 5 years</p></td>
<td align="center">
<p style="text-indent:0em;">8 to 10</p></td>
<td align="center">
<p style="text-indent:0em;">−</p></td>
<td align="center">
<p style="text-indent:0em;">6 to 9</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">5 to 10 years</p></td>
<td align="center">
<p style="text-indent:0em;">5 to 10</p></td>
<td align="center">
<p style="text-indent:0em;">6 to 12</p></td>
<td align="center">
<p style="text-indent:0em;">4 to 8</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;">&gt;10 years</p></td>
<td align="center">
<p style="text-indent:0em;">2.5 to 5</p></td>
<td align="center">
<p style="text-indent:0em;">2.5 to 5</p></td>
<td align="center">
<p style="text-indent:0em;">2 to 3</p></td></tr></tbody></table></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="92e477a9-5d93-49a7-baca-15c656890bd3">Tachyarrhythmias, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Tachyarrhythmias, treatment:</b> Limited data available (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22907424']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22907424'])">Ref</a></span>): Injection, Oral: Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Initial (digitalizing dose):</p>
<p style="text-indent:-2em;margin-left:6em;">IV: 10 to 12 mcg/kg/dose every 8 hours for 3 doses</p>
<p style="text-indent:-2em;margin-left:6em;">Oral: 13 to 17 mcg/kg/dose every 8 hours for 3 doses</p>
<p style="text-indent:-2em;margin-left:4em;">Maintenance: Oral: 8 to 10 mcg/kg/day divided once or twice daily (Escudero 2012); use twice daily dosing in infants and young children (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7560629']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7560629'])">Ref</a></span>)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51109234"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:4em;">Infants, Children, and Adolescents: Oral, IV:</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Digitalizing (loading) dose</i>: There are no dosage adjustments provided in the manufacturer's labeling for digitalizing dose; however, 50% to 70% of a digoxin dose is excreted unchanged in the urine. The following adjustments have been recommended in adults with end-stage renal disease (ESRD): Reduce usual dose by 50% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Maintenance dose</i>:</p>
<p style="text-indent:-2em;margin-left:8em;">Manufacturer's labeling: Dosage reductions and close monitoring recommended; see product labeling for CrCl-specific dosage recommendation</p>
<p style="text-indent:-2em;margin-left:8em;">Alternate dosing: The following adjustments have been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Aronoff.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Aronoff.1'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:10em;">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary</p>
<p style="text-indent:-2em;margin-left:10em;">GFR: 30 to 50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of normal dose at normal intervals</p>
<p style="text-indent:-2em;margin-left:10em;">GFR: 10 to 29 mL/minute/1.73 m<sup>2</sup>: Administer 50% of normal dose at normal intervals <b>or</b> administer normal dose every 36 hours</p>
<p style="text-indent:-2em;margin-left:10em;">GFR: &lt;10 mL/minute/1.73 m<sup>2</sup>: Administer 25% of normal dose at normal intervals <b>or</b> administer normal dose every 48 hours</p>
<p style="text-indent:-2em;margin-left:10em;">Intermittent hemodialysis: Nondialyzable (0% to 5%). Administer 25% of normal dose at normal intervals <b>or</b> administer normal dose every 48 hours</p>
<p style="text-indent:-2em;margin-left:10em;">Peritoneal dialysis (PD): Administer 25% of normal dose at normal intervals <b>or</b> administer normal dose every 48 hours</p>
<p style="text-indent:-2em;margin-left:10em;">Continuous renal replacement therapy (CRRT): Administer 75% of normal dose at normal intervals; titrate to desired effect; monitor serum concentrations</p></div>
<div class="block dohp drugH1Div" id="F51109235"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block arsc drugH1Div" id="F55027362"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Digoxin toxicity</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Digoxin toxicity in adult and pediatric patients is typically associated with levels &gt;2 ng/mL; however, due to its narrow therapeutic window, digoxin toxicity is possible at therapeutic levels (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>). Digoxin serum concentrations obtained &lt;6 hours after ingestion may appear falsely elevated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27041802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27041802'])">Ref</a></span>). Symptoms of digoxin toxicity may include <b>nausea, vomiting, visual disturbances </b>(“halos,” yellow or<b> blurred vision</b>),<b> lethargy,</b> and/or life-threatening arrhythmias. Arrhythmias may include paroxysmal <b>atrial tachycardia</b>, atrioventricular (AV) block (all types; <b>first degree</b>
<b>atrioventricular block</b>, <b>second degree atrioventricular block</b>, <b>complete atrioventricular block</b> [Mobitz type II more unlikely]), <b>and</b>
<b> ventricular premature contractions. </b>In severe cases, arrythmias may include <b>ventricular tachycardia</b> (bidirectional) or <b>ventricular fibrillation</b>. Children are more likely to experience cardiac arrhythmia as a sign of excessive dosing; CNS and GI symptoms are not frequently observed. Conduction disturbances or tachyarrhythmia (atrial tachycardia with or without block) and junctional tachycardia are most common. Sinus bradycardia may be a sign of digoxin toxicity, especially in infants. Ventricular tachyarrhythmias are less common. Cardiac arrhythmias are the primary cause of death associated with digoxin toxicity and may present without any additional symptoms. Digoxin toxicity is reversible upon discontinuation or administration of digoxin immune fab (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11207409','lexi-content-ref-27041802','lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11207409','lexi-content-ref-27041802','lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Serum concentration-related; related to the pharmacologic action. Increased intracellular calcium and increased activation of the parasympathetic nervous system due to significant inhibition of the Na+/K+ ATPase pump and AV nodal blockade, respectively, lead to increased automaticity and decreased conduction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; serum concentration-related; acute and chronic toxicity may occur (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27041802']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27041802'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>
<i>:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Digoxin concentration &gt;2 ng/mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1997015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1997015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Chronic obstructive pulmonary disease (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1997015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1997015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hypothyroidism (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1100180','lexi-content-ref-3325214','lexi-content-ref-1997015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1100180','lexi-content-ref-3325214','lexi-content-ref-1997015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Kidney impairment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996','lexi-content-ref-1997015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996','lexi-content-ref-1997015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Electrolyte disturbances (eg, hypercalcemia, hypokalemia, hypomagnesemia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32929996','lexi-content-ref-1997015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32929996','lexi-content-ref-1997015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Dehydration/over-diuresis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-1997015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-1997015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Amyloidosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17000935']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17000935'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of interacting medications that increase digoxin concentration (eg, amiodarone, dronedarone, erythromycin, itraconazole, lapatinib, propafenone, quinidine, ranolazine, ritonavir, verapamil) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7094655','lexi-content-ref-32929996','lexi-content-ref-1997015']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7094655','lexi-content-ref-32929996','lexi-content-ref-1997015'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F160108"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Accelerated atrioventricular junctional rhythm, asystole, atrial tachycardia (Tisdale 2020) atrioventricular dissociation, complete atrioventricular block (Mahdyoon 1990; Tisdale 2020), depression of ST segment on ECG, first degree atrioventricular block (Mahdyoon 1990; Tisdale 2020), prolongation P-R interval on ECG, second degree atrioventricular block (Mahdyoon 1990; Tisdale 2020), ventricular fibrillation (Ma 2001; Tisdale 2020), ventricular premature contractions (Ma 2001), ventricular tachycardia (Ma 2001; Tisdale 2020)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (bullous, erythematous, maculopapular [most common], papular, scarlatiniform, vesicular) (Martin 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, anorexia, diarrhea, intestinal necrosis (hemorrhagic), mesenteric ischemia, nausea (Limon 2016), vomiting (Limon 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Thrombocytopenia (Pirovino 1981)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Altered mental status, anxiety, apathy, confusion, delirium, depression, dizziness, hallucination, headache, lethargy (Pincus 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Asthenia</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, visual disturbances (blurred or yellow vision) (Limon 2016), xanthopsia</p></div>
<div class="block coi drugH1Div" id="F160123"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to digoxin, other forms of digitalis, or any component of the formulation; ventricular fibrillation</p></div>
<div class="block war drugH1Div" id="F160105"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Extravasation: IV administration: Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Accessory bypass tract (eg, Wolff-Parkinson-White [WPW] syndrome): During an episode of atrial fibrillation or flutter in patients with an accessory bypass tract or pre-excitation syndrome, use has been associated with increased anterograde conduction down the accessory pathway leading to ventricular fibrillation; avoid use in such patients (ACLS [Neumar 2010]; AHA/ACC/HRS [January 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Acute coronary syndrome: Use with caution in patients with an acute MI; may increase myocardial oxygen demand and lead to ischemia. During an acute coronary syndrome, digoxin administered IV may be used to slow a rapid ventricular response and improve left ventricular (LV) function in the acute treatment of atrial fibrillation associated with severe LV function and heart failure or hemodynamic instability (AHA/ACC/HRS [January 2014]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Atrial fibrillation: When used for rate control in patients with atrial fibrillation, monitor serum concentrations closely; may be associated with an increased risk of mortality especially when serum concentrations are not properly controlled (Vamos 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Beri beri heart disease: Patients with beri beri heart disease may fail to adequately respond to digoxin therapy; treat underlying thiamine deficiency concomitantly.</p>
<p style="text-indent:-2em;margin-left:4em;">• Electrolyte imbalance: Correct electrolyte disturbances, especially hypokalemia or hypomagnesemia, prior to use and throughout therapy. Hypercalcemia may increase the risk of digoxin toxicity and hypocalcemia can nullify the effects of digoxin; maintain normocalcemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Heart failure with reduced ejection fraction: Digoxin should be considered for use only in heart failure (HF) with reduced ejection fraction (HFrEF) when symptoms remain despite guideline-directed medical therapy. It may also be considered in patients with both HF and atrial fibrillation; however, beta blockers may offer better ventricular rate control than digoxin (AHA/ACC/HFSA [Heidenreich 2022]). Withdrawal of digoxin in clinically stable patients with HF may lead to recurrence of HF symptoms (Packer 1993). Monitor serum concentrations closely; may be associated with an increased risk of mortality especially when serum concentrations are not properly controlled (Vamos 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypermetabolic states: Atrial arrhythmias associated with hypermetabolic (eg, hyperthyroidism) or hyperdynamic (hypoxia, arteriovenous shunt) states are very difficult to treat; treat underlying condition first. If digoxin is used, ensure digoxin toxicity does not occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertrophic cardiomyopathy with left ventricular outflow tract obstruction: Outflow obstruction may worsen due to the positive inotropic effects of digoxin; avoid use unless used to control ventricular response with atrial fibrillation. Digoxin is potentially harmful in the treatment of dyspnea in patients with HCM in the absence of atrial fibrillation (AHA/ACC [Ommen 2020]).</p>
<p style="text-indent:-2em;margin-left:4em;">• Kidney impairment: Use with caution in patients with kidney impairment; dosage adjustment needed.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myocarditis: In a murine model of viral myocarditis, digoxin in high doses was shown to be detrimental (Matsumori 1999). If used in humans, therefore, digoxin should be used with caution and only at low doses (Frishman 2007). The manufacturer recommends avoiding the use of digoxin in patients with myocarditis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Preserved left ventricular function: Decreased cardiac output may occur in patients with preserved left ventricular systolic function, including restrictive or hypertrophic cardiomyopathy, constrictive pericarditis, amyloid heart disease, and acute cor pulmonale; in general, the manufacturer recommends to avoid use unless used to control ventricular response with atrial fibrillation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sinus node disease and atrioventricular (AV) block: Because digoxin slows sinoatrial and AV conduction, the drug commonly prolongs the PR interval. Digoxin may cause severe sinus bradycardia or sinoatrial block particularly in patients with preexisting sinus node disease. Avoid use in patients with second- or third-degree heart block (except in patients with a functioning artificial pacemaker); incomplete AV block (eg, Stokes-Adams attacks) may progress to complete block with digoxin administration. In such patients, if treatment with digoxin is necessary, consider the insertion of a pacemaker before treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thyroid disease: Use with caution in patients with hypothyroidism, higher digoxin concentrations may result due to significant reduction in digoxin clearance (Burk 2010). In patients with hyperthyroidism, lower digoxin concentrations may result due to an increase in renal clearance of digoxin. No significant differences in absorption were seen in either thyroid condition compared with those with normal thyroid function (Burk 2010). <b>Note:</b> New-onset atrial fibrillation or exacerbation of ventricular arrhythmias should prompt evaluation of thyroid status.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infants: Newborn infants display considerable variability to their tolerance to digoxin; premature and immature infants are particularly sensitive to the effects of digoxin.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Zar 2007).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Elective electrical cardioversion: It is not necessary to routinely reduce or hold digoxin therapy prior to elective electrical cardioversion for atrial fibrillation; however, exclusion of digoxin toxicity (eg, clinical and ECG signs) is necessary prior to cardioversion. If signs of digoxin excess exist, withhold digoxin and delay cardioversion until toxicity subsides (AHA/ACC/HRS [January 2014]).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878425"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Some dosage forms may contain propylene glycol; in neonates, large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>
<div class="block foc drugH1Div" id="F160116"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lanoxin: 0.25 mg/mL (2 mL) [contains alcohol, usp, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lanoxin Pediatric: 0.1 mg/mL (1 mL) [contains alcohol, usp, propylene glycol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05 mg/mL (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Digitek: 125 mcg [DSC] [scored; contains quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Digitek: 250 mcg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Digox: 125 mcg [DSC] [scored; contains quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Digox: 250 mcg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lanoxin: 62.5 mcg [contains corn starch, fd&amp;c yellow #6 (sunset yellow)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lanoxin: 125 mcg [scored; contains fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lanoxin: 250 mcg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lanoxin: 250 mcg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 62.5 mcg, 125 mcg, 250 mcg</p></div>
<div class="block geq drugH1Div" id="F160101"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F160125"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Digoxin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/mL (per mL): $3.30 - $3.74</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Digoxin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.05 mg/mL (per mL): $2.48 - $2.84</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lanoxin Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.25 mg/mL (per mL): $75.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Lanoxin Pediatric Injection)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1 mg/mL (per mL): $151.63</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Digoxin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5 mcg (per each): $13.82 - $15.55</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $0.45 - $4.56</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg (per each): $0.45 - $4.56</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Lanoxin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">62.5 mcg (per each): $19.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">125 mcg (per each): $19.86</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mcg (per each): $19.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52866594"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Lanoxin: 0.25 mg/mL ([DSC]) [contains alcohol, usp]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.25 mg/mL (2 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.05 mg/mL (115 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 62.5 mcg, 125 mcg, 250 mcg, 0.0625 mg, 0.125 mg</p></div>
<div class="block adm drugH1Div" id="F803126"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IM: IV route preferred. If IM injection necessary, administer by deep injection followed by massage at the injection site. Inject no more than 2 mL per injection site. May cause intense pain.</p>
<p style="text-indent:-2em;margin-left:2em;">IV: May be administered undiluted or diluted. Inject slowly over ≥5 minutes.</p>
<p style="text-indent:-2em;margin-left:2em;">When used for the management of fetal tachycardia (off-label use), IV or oral doses are administered to the mother for transplacental transfer to the fetus (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24763516']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24763516'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b> Extravasation management:</b> If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p></div>
<div class="block admp drugH1Div" id="F52612558"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Neonatal, Infants, Children, and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral: Administer consistently with relationship to meals; avoid concurrent administration (ie, administer digoxin 1 hour before or 2 hours after) with meals high in fiber or pectin and with drugs that decrease oral absorption of digoxin.</p>
<p style="text-indent:-2em;margin-left:6em;">Oral solution: Only the calibrated manufacturer-provided dropper or a calibrated oral syringe should be used to measure the dose. For doses &lt;0.2 mL the manufacturer-provided dropper is not accurate and should not be used; use a calibrated oral syringe.</p>
<p style="text-indent:-2em;margin-left:4em;">Parenteral:</p>
<p style="text-indent:-2em;margin-left:6em;">IV: May be slowly administered IV over ≥5 minutes (usually 5 to 10 minutes); avoid rapid IV infusion since this may result in systemic and coronary arteriolar vasoconstriction.</p>
<p style="text-indent:-2em;margin-left:8em;">Vesicant; ensure proper needle or catheter placement prior to and during administration; avoid extravasation. If extravasation occurs, stop IV administration immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity.</p>
<p style="text-indent:-2em;margin-left:6em;">IM: Not usually recommended due to local irritation, pain, and tissue damage; if necessary, administer by deep injection followed by massage at the injection site. May cause intense pain.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>FETAL:</b> IM: Administer into FETAL buttock or thigh under direct ultrasound guidance.</p></div>
<div class="block use drugH1Div" id="F160120"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Atrial fibrillation or atrial flutter, rate control:</b> Control of ventricular response rate in adults with chronic atrial fibrillation.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Heart failure with reduced ejection fraction (HFrEF):</b> Treatment of mild to moderate (or stage C as recommended by the ACCF/AHA) heart failure in adults; to increase myocardial contractility in pediatric patients with heart failure</p></div>
<div class="block off-label drugH1Div" id="F25725522"><span class="drugH1">Use: Off-Label: Adult</span><p>Fetal supraventricular tachyarrhythmia, sustained (maternal administration for transplacental transfer to the fetus); Supraventricular tachycardia (eg, atrioventricular nodal reentrant tachycardia), rate control</p></div>
<div class="block mst drugH1Div" id="F160198"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:0em;margin-left:2em;">Digoxin may be confused with Desoxyn, doxepin</p>
<p style="text-indent:-2em;margin-left:4em;">Lanoxin may be confused with Lasix, levothyroxine, Levoxyl, Levsinex, Lomotil, Mefoxin, naloxone, Xanax</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Digoxin is identified in the Beers Criteria as a potentially inappropriate medication to be avoided in patients 65 years and older as first-line therapy for atrial fibrillation (due to safer and more effective alternatives for rate control) or as first-line therapy for heart failure (due to conflicting and low quality evidence for benefits and harms, evidence that other agents decrease hospitalizations and mortality, and lack of additional benefit when higher doses are used despite the increased risk of toxicity). Exercise caution when discontinuing therapy in patients with heart failure with reduced ejection fraction due to limited evidence suggesting worse outcomes following discontinuation. If used, avoid doses greater than 0.125 mg/day due to decreased renal clearance of digoxin which may result in increased risk of toxic effects; further dose reductions may be warranted in patients with Stage 4 or 5 chronic kidney disease (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Lanoxin [US, Canada, and multiple international markets] may be confused with Limoxin brand name for ambroxol [Indonesia] and amoxicillin [Mexico]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F160185"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor), P-glycoprotein/ABCB1 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F160110"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">5-Aminosalicylic Acid Derivatives: May decrease the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acarbose: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Adenosine: Digoxin may enhance the adverse/toxic effect of Adenosine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminoglycosides: May decrease the serum concentration of Cardiac Glycosides. This effect has only been demonstrated with oral aminoglycoside administration.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May increase the serum concentration of Cardiac Glycosides. Management: Reduce the dose of cardiac glycosides by 30% to 50%  or reduce the frequency of administration when initiating concomitant amiodarone therapy. Monitor for increased serum concentrations and toxic effects of cardiac glycosides.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphotericin B: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagliptin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antithyroid Agents: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asciminib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Asunaprevir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atorvastatin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Barnidipine: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Benidipine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Berotralstat: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bretylium: May enhance the adverse/toxic effect of Cardiac Glycosides. Management: Bretylium should only be used in digitalis-treated patients when other antiarrhythmic options are ineffective and when arrhythmia is not suspected to be related to digitalis toxicity. Bretylium is contraindicated in digitalis-induced arrhythmias.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brimonidine (Topical): May enhance the bradycardic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Channel Blockers (Nondihydropyridine): May enhance the AV-blocking effect of Cardiac Glycosides. Calcium Channel Blockers (Nondihydropyridine) may increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Polystyrene Sulfonate: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, the risk for increased digoxin toxicity may occur if hypokalemia is present.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Calcium Salts: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Canagliflozin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: Digoxin may enhance the bradycardic effect of Carvedilol. Carvedilol may increase the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ceritinib: Bradycardia-Causing Agents may enhance the bradycardic effect of Ceritinib.  Management: If this combination cannot be avoided, monitor patients for evidence of symptomatic bradycardia, and closely monitor blood pressure and heart rate during therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cobicistat: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: Digoxin may enhance the adverse/toxic effect of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Conivaptan: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Diacerein: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dronedarone: Digoxin may enhance the AV-blocking effect of Dronedarone. Digoxin may also enhance the other electrophysiologic effects of Dronedarone. Dronedarone may increase the serum concentration of Digoxin.  Management: Avoid concurrent use of digoxin when possible. If concurrent use is necessary, reduce digoxin dose by 50%, monitor digoxin concentration closely, and increase monitoring for both clinical response to therapy and the occurrence of adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edrophonium: May enhance the AV-blocking effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elacestrant: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enasidenib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Nasal): Cardiac Glycosides may enhance the arrhythmogenic effect of EPHEDrine (Nasal). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">EPHEDrine (Systemic): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Epoprostenol: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erdafitinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: If coadministration with these narrow therapeutic index/sensitive P-gp substrates is unavoidable, separate erdafitinib administration by at least 6 hours before or after administration of these P-gp substrates.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etrasimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etravirine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fexinidazole: Bradycardia-Causing Agents may enhance the arrhythmogenic effect of Fexinidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fingolimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Fingolimod.  Management: Consult with the prescriber of any bradycardia-causing agent to see if the agent could be switched to an agent that does not cause bradycardia prior to initiating fingolimod. If combined, perform continuous ECG monitoring after the first fingolimod dose.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flibanserin: May increase the serum concentration of Digoxin. Management: Measure digoxin serum concentrations before initiating treatment with flibanserin. Reduce digoxin concentrations by either reducing the digoxin dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">FLUoxetine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Futibatinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glycopyrrolate (Systemic): May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hydroxychloroquine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Istradefylline: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: May increase the serum concentration of Cardiac Glycosides. Management: Measure cardiac glycoside serum concentrations before initiating treatment with itraconazole. Reduce cardiac glycoside concentrations by either reducing the dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ivabradine: Bradycardia-Causing Agents may enhance the bradycardic effect of Ivabradine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Kaolin: May decrease the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lacosamide: Bradycardia-Causing Agents may enhance the AV-blocking effect of Lacosamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lapatinib: May increase the serum concentration of Digoxin. Management: Measure digoxin serum concentrations before initiating treatment with lapatinib. Reduce digoxin concentrations by either reducing the digoxin dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenacapavir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lenalidomide: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levosulpiride: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, levosulpiride may diminish symptoms of cardiac glycoside-related toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Licorice: May enhance the adverse/toxic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lonafarnib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Loop Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of loop diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Digoxin. Lumacaftor and Ivacaftor may increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Macrolide Antibiotics: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maribavir: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaraminol: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">MetroNIDAZOLE (Systemic): May enhance the adverse/toxic effect of Products Containing Propylene Glycol. A disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Midodrine: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Milnacipran: May enhance the adverse/toxic effect of Digoxin. The risk of postural hypotension and tachycardia may be increased.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mirabegron: May increase the serum concentration of Digoxin. Management: Consider initiating the lowest dose of digoxin in patients beginning treatment with a combination of digoxin and mirabegron. Monitor digoxin concentrations and adjust the digoxin dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitapivat: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular-Blocking Agents: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">NIFEdipine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirmatrelvir and Ritonavir: May increase the serum concentration of Digoxin. Management: Reduce the digoxin dose by approximately 30% to 50%, or reduce the dosing frequency, when these agents are combined. Monitor digoxin levels closely and adjust digoxin dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nitrendipine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: May enhance the bradycardic effect of Digoxin. Octreotide may increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Propylene Glycol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pacritinib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Parathyroid Hormone: May enhance the adverse/toxic effect of Cardiac Glycosides. More specifically, Parathyroid Hormone-related hypercalcemia may predispose to digitalis toxicity.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Paricalcitol: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pectin: May decrease the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PenicillAMINE: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of Digoxin. Management: Measure digoxin serum concentrations before initiating treatment with these P-glycoprotein (P-gp) inhibitors. Reduce digoxin concentrations by either reducing the digoxin dose by 15% to 30% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol 3350: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol 4000: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Polyethylene Glycol-Electrolyte Solution: May decrease the absorption of Digoxin. Management: Give oral digoxin at least 2 hours before or at least 6 hours after polyethylene glycol-electrolyte solutions that contain magnesium sulfate (Suflave brand). Other products without magnesium do not require dose separation.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ponesimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Ponesimod.  Management: Avoid coadministration of ponesimod with drugs that may cause bradycardia when possible. If combined, monitor heart rate closely and consider obtaining a cardiology consult. Do not initiate ponesimod in patients on beta-blockers if HR is less than 55 bpm.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pretomanid: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: May increase the serum concentration of Cardiac Glycosides. Management: Measure cardiac glycoside serum concentrations before initiating treatment with propafenone. Reduce cardiac glycoside concentrations by either reducing the dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propantheline: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QuiNIDine: May increase the serum concentration of Cardiac Glycosides. Management: Measure cardiac glycoside serum concentrations before initiating treatment with quinidine. Reduce cardiac glycoside concentrations by either reducing the dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinidine (Non-Therapeutic): May increase the serum concentration of Cardiac Glycosides. Management: Measure cardiac glycoside serum concentrations before initiating treatment with quinidine. Reduce cardiac glycoside concentrations by either reducing the dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ranolazine: May increase the serum concentration of Digoxin. Management: Measure digoxin serum concentrations before initiating treatment with ranolazine. Reduce digoxin concentrations by either reducing the digoxin dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Reserpine: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritonavir: May increase the serum concentration of Digoxin. Management: Reduce the digoxin dose by approximately 30% to 50%, or reduce the dosing frequency, when these agents are combined. Monitor digoxin levels closely and adjust digoxin dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Roxithromycin: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sarecycline: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Propylene Glycol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Senna: May enhance the adverse/toxic effect of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Siponimod: Bradycardia-Causing Agents may enhance the bradycardic effect of Siponimod.  Management: Avoid coadministration of siponimod with drugs that may cause bradycardia. If combined, consider obtaining a cardiology consult regarding patient monitoring.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors). Management: Consider avoiding use of sotorasib and narrow therapeutic index/sensitive P-gp substrates. If combined use is unavoidable, monitor for increased toxicities of the substrate and consider a decrease in the substrate dosage.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Spironolactone: May increase the serum concentration of Digoxin. Spironolactone (and/or its metabolites) may also interfere with the assays used to determine Digoxin concentrations, falsely increasing or decreasing Digoxin concentrations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sucralfate: May decrease the serum concentration of Digoxin. Specifically, sucralfate may decrease the absorption of digoxin. Management: Administer digoxin at least 2 hours before sucralfate. Concomitant administration should be avoided. Monitor for decreased digoxin levels/effects with initiation of sucralfate therapy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Taurursodiol: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates (Narrow Therapeutic Index/Sensitive with Inhibitors).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Telmisartan: May increase the serum concentration of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May enhance the adverse/toxic effect of Cardiac Glycosides. Specifically, cardiac glycoside toxicity may be enhanced by the hypokalemic and hypomagnesemic effect of thiazide diuretics.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: May decrease the serum concentration of Cardiac Glycosides. Specifically, returning to a euthyroid state from a hypothyroid state may decrease the serum concentration of cardiac glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ticagrelor: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tofacitinib: May enhance the bradycardic effect of Bradycardia-Causing Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tolvaptan: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimethoprim: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vandetanib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vemurafenib: May increase the serum concentration of Digoxin. Management: Avoid coadministration of vemurafenib and digoxin when possible. If combined, measure digoxin levels and reduce digoxin concentrations by either reducing the digoxin dose by 30% to 50% or by modifying the dosing frequency.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venetoclax: May increase the serum concentration of Digoxin. Management: Avoid concomitant use of venetoclax and digoxin if possible. If combined, administer digoxin at least 6 hours before venetoclax to minimize the potential for an interaction.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vibegron: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vilazodone: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin D Analogs: May enhance the arrhythmogenic effect of Cardiac Glycosides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May increase the serum concentration of Digoxin.<i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F160139"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;display:inline">Digoxin peak serum concentrations may be decreased if taken with food. Meals containing increased fiber (bran) or foods high in pectin may decrease oral absorption of digoxin.</p></div>
<div class="block pri drugH1Div" id="F9729170"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Digoxin crosses the placenta.</p>
<p style="text-indent:0em;margin-top:2em;">Available guidelines note experience with digoxin in pregnancy is extensive (ESG [Regitz-Zagrosek 2018]). Based on available data, an increased risk of adverse pregnancy outcomes has not been observed. However, untreated maternal heart failure and atrial fibrillation may increase the risk of preterm birth and low birth weight, respectively. The manufacturer recommends monitoring neonates for signs and symptoms of digoxin toxicity following in utero exposure.</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes, some pharmacokinetic properties of digoxin may be altered. Close monitoring of maternal serum digoxin is recommended (Hebert 2008; Luxford 1983; Martin-Suarez 2017); dose adjustments may be required during pregnancy and postpartum.</p>
<p style="text-indent:0em;margin-top:2em;">Heart failure and atrial fibrillation may worsen during pregnancy. Digoxin is recommended as a first-line agent for the chronic treatment of highly symptomatic supraventricular tachycardia (SVT) in pregnancy; the lowest effective dose is recommended (ACC/AHA/HRS [Page 2015]). Digoxin may be considered for long-term rate control of maternal atrial tachycardia or atrial fibrillation when preferred agents fail (ESG [Regitz-Zagrosek 2018]). Monitor for an increased risk of maternal arrhythmias during labor and delivery.</p>
<p style="text-indent:0em;margin-top:2em;">Digoxin may be considered for the in utero management of fetal SVT or atrial flutter with hydrops or ventricular dysfunction. Digoxin may also be considered for SVT without hydrops or ventricular dysfunction if heart rate is ≥200 bpm, atrial flutter, or other rare tachycardias with an average heart rate of ≥200 bpm (AHA [Donofrio 2014]).</p></div>
<div class="block brc drugH1Div" id="F9729172"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;">Digoxin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">The manufacturer reports the relative infant dose (RID) of digoxin to be 1% to 7% of a weight-adjusted maternal dose or ~ 0.2% to 4% of a neonatal maintenance dose.</p>
<p style="text-indent:-2em;margin-left:2em;">In general, breastfeeding is considered acceptable when the RID of a medication is &lt;10% (Anderson 2016; Ito 2000).</p>
<p style="text-indent:-2em;margin-left:2em;">The RID of digoxin was calculated by the manufacturer using milk concentrations of 0.4 to 1 ng/mL, providing an estimated daily infant dose via breast milk of 0.03 to 0.16 mcg/kg/day. This milk concentration was obtained following maternal administration of digoxin 0.25 mg once daily to 13 lactating women. Higher milk concentrations (&lt;12 ng/mL) were obtained following an IV bolus dose of 500 mcg to 1 breastfeeding woman; however, digoxin levels rapidly decreased to ~1 ng/mL ~2 hours after the injection. This study found milk concentrations declined in parallel to maternal serum concentrations following either oral or IV dosing (Reinhardt 1982). Digoxin can be detected in the serum of breastfed infants (Finley 1979).</p>
<p style="text-indent:-2em;margin-left:2em;">The amount of digoxin available to the infant via breast milk is not likely to be clinically significant. The World Health Organization considers digoxin to be compatible with breastfeeding (WHO 2002).</p></div>
<div class="block dic drugH1Div" id="F160126"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Maintain adequate amounts of potassium in diet to decrease risk of hypokalemia (hypokalemia may increase risk of digoxin toxicity).</p></div>
<div class="block mop drugH1Div" id="F160114"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Heart rate and rhythm should be monitored along with periodic ECGs to assess desired effects and signs of toxicity; baseline and periodic serum creatinine. Periodically monitor serum potassium, magnesium, and calcium especially if on medications where these electrolyte disturbances can occur (eg, diuretics), or if patient has a history of hypokalemia or hypomagnesemia. Observe patients for noncardiac signs of toxicity, confusion, and depression.</p>
<p style="text-indent:-2em;margin-left:2em;">When to draw serum digoxin concentrations: Digoxin serum concentrations are monitored because digoxin possesses a narrow therapeutic serum range; the therapeutic endpoint is difficult to quantify and digoxin toxicity may be life-threatening. Digoxin serum concentrations should be drawn <b>at least 6 to 8 hours after last dose, regardless of route of administration (optimally 12 to 24 hours after a dose). Note:</b> Serum digoxin concentrations may decrease in response to exercise due to increased skeletal muscle uptake; a period of rest (eg, ~2 hours) after exercise may be necessary prior to drawing serum digoxin concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">Initiation of therapy:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>If a loading dose is given:</b> Digoxin serum concentration may be drawn within 12 to 24 hours after the initial loading dose administration. Concentrations drawn this early may confirm the relationship of digoxin plasma concentrations and response but are of little value in determining maintenance doses.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>If a loading dose is not given:</b> Digoxin serum concentration should be obtained after 3 to 5 days of therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">Maintenance therapy:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Trough</b> concentrations should be followed just prior to the next dose or at a minimum of 6 to 8 hours after last dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Digoxin serum concentrations should be obtained within 5 to 7 days (approximate time to steady-state) after any dosage changes. Continue to obtain digoxin serum concentrations 7 to 14 days after any change in maintenance dose. <b>Note:</b> In patients with end-stage kidney disease, it may take 15 to 20 days to reach steady-state.</p>
<p style="text-indent:-2em;margin-left:4em;">Patients who are receiving electrolyte-depleting medications such as diuretics, serum potassium, magnesium, and calcium should be monitored closely.</p>
<p style="text-indent:-2em;margin-left:4em;">Digoxin serum concentrations should be obtained whenever any of the following conditions occur:</p>
<p style="text-indent:-2em;margin-left:6em;">Questionable patient compliance or to evaluate clinical deterioration following an initial good response</p>
<p style="text-indent:-2em;margin-left:6em;">Changing kidney function</p>
<p style="text-indent:-2em;margin-left:6em;">Suspected digoxin toxicity</p>
<p style="text-indent:-2em;margin-left:6em;">Initiation or discontinuation of therapy with drugs (eg, amiodarone, quinidine, verapamil) which potentially interact with digoxin.</p>
<p style="text-indent:-2em;margin-left:6em;">Any disease changes (eg, thyroid disease)</p></div>
<div class="block rer drugH1Div" id="F160117"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Digoxin therapeutic serum concentrations:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Heart failure: 0.5 to 0.9 ng/mL (SI: 0.6 to 1.2 nmol/L) (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:6em;">Toxic: Risk (including mortality) increases with serum concentrations &gt;1.2 ng/mL (SI: &gt;1.5 nmol/L), but toxicity can occur at any time and may occur at lower levels in the setting of hypokalemia, hypomagnesemia, or hypothyroidism (AHA/ACC/HFSA [Heidenreich 2022]).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">Atrial fibrillation: 0.8 to 2 ng/mL (SI: 1 to 2.6 nmol/L); &lt;0.5 ng/mL (SI: &lt;0.6 nmol/L) probably indicates underdigitalization unless there are special circumstances. A serum concentration ≥1.2 ng/mL (SI: ≥1.5 nmol/L) may be associated with increased all-cause mortality in patients with atrial fibrillation (regardless of heart failure) (Lopes 2018).</p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin-like immunoreactive substance (DLIS) may cross-react with digoxin immunoassay. DLIS has been found in patients with kidney and liver disease, heart failure, neonates, and pregnant women (third trimester).</p></div>
<div class="block pha drugH1Div" id="F160104"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:-2em;margin-left:2em;">Heart failure: Inhibition of the sodium/potassium ATPase pump in myocardial cells results in a transient increase of  intracellular sodium, which in turn promotes calcium influx via the sodium-calcium exchange pump leading to increased contractility. May improve baroreflex sensitivity (Gheorghiade 1991).</p>
<p style="text-indent:-2em;margin-left:2em;">Supraventricular arrhythmias: Direct suppression of the AV node conduction to increase effective refractory period and decrease conduction velocity - positive inotropic effect, enhanced vagal tone, and decreased ventricular rate to fast atrial arrhythmias. Atrial fibrillation may decrease sensitivity and increase tolerance to higher serum digoxin concentrations.</p></div>
<div class="block phk drugH1Div" id="F160122"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Heart rate control: Oral: 1 to 2 hours; IV: 5 to 60 minutes.</p>
<p style="text-indent:-2em;margin-left:4em;">Peak effect: Heart rate control: Oral: 2 to 8 hours; IV: 1 to 6 hours; <b>Note:</b> In patients with atrial fibrillation, median time to ventricular rate control in one study was 6 hours (range: 3 to 15 hours) (Siu 2009).</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: Adults: 3 to 4 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: By passive nonsaturable diffusion in the upper small intestine; food may delay, but does not affect extent of absorption.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Normal kidney function: 6 to 7 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">V<sub>d</sub>: Extensive to peripheral tissues, with a distinct distribution phase which lasts 6 to 8 hours; concentrates in heart, liver, kidney, skeletal muscle, and intestines. Heart/serum concentration is 70:1. Pharmacologic effects are delayed and do not correlate well with serum concentrations during distribution phase.</p>
<p style="text-indent:-2em;margin-left:4em;">Hyperthyroidism: Increased V<sub>d</sub>.</p>
<p style="text-indent:-2em;margin-left:4em;">Hyperkalemia, hyponatremia: Decreased digoxin distribution to heart and muscle.</p>
<p style="text-indent:-2em;margin-left:4em;">Hypokalemia: Increased digoxin distribution to heart and muscles.</p>
<p style="text-indent:-2em;margin-left:4em;">Concomitant quinidine therapy: Decreased V<sub>d</sub>.</p>
<p style="text-indent:-2em;margin-left:4em;">Chronic kidney failure: 4 to 6 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Decreased sodium/potassium ATPase activity - decreased tissue binding.</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates, full-term: 7.5 to 10 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 16 L/kg.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 7 L/kg, decreased with kidney disease.</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~25%; in uremic patients, digoxin is displaced from plasma protein binding sites.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Via sequential sugar hydrolysis in the stomach or by reduction of lactone ring by intestinal bacteria (in ~10% of population, gut bacteria may metabolize up to 40% of digoxin dose); once absorbed, only ~16% is metabolized to 3-beta-digoxigenin, 3-keto-digoxigenin, and glucuronide and sulfate conjugates; metabolites may contribute to therapeutic and toxic effects of digoxin; metabolism is reduced with decompensated HF.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Oral (formulation dependent): Elixir: 70% to 85%; Tablet: 60% to 80%.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination (age, renal and cardiac function dependent):</p>
<p style="text-indent:-2em;margin-left:4em;">Neonates: Premature: 61 to 170 hours; Full-term: 35 to 45 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Infants: 18 to 25 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children: 18 to 36 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: 36 to 48 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults, anephric: 3.5 to 5 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Parent drug: 38 hours; Metabolites: Digoxigenin: 4 hours; Monodigitoxoside: 3 to 12 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, serum: Oral: 1 to 3 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (50% to 70% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51153948"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Clearance correlates with CrCl. Half-life is 3.5 to 5 days in anuric patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F160127"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Lanicor | Lanoxin | Lanoxin pg | Toloxin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Cardiogoxin | Digocard-g | Digoxina | Lanicor | Lanoxin (igoxina)</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Lanicor | Novodigal</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin | Sigmaxin</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Agoxin | Centoxin | Lanoxin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Digoxine nativelle | Lanoxin | Lanoxin Digoxine</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Dilacor | Novodigal</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Beldigox | Cardcor | Cardionil | Cimecard | Digitax | Digixina | Digobal | Digox | Digoxan | Digoxen | Digoxil | Digoxina | Furp digoxina | Lanoxin | Neo digoxin | Valoxin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Digoxin juvise | Digoxin mepha | Digoxin streuli | Digoxine labatec | Lanoxin</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Digoxina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ke li</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Digicor | Digoxina</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Digoxin nativelle | Digoxin orion | Lanicor</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Digacin | Digoxin digoregen | Digoxin Goedecke | Dilanacin | Lanicor | Lenoxin</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Digoxina | Digoxina Inmenol | Lanicor | Lanigoxina | Lanoxin</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Digoxina | Lanicor</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Digoxin ns | Lanicor | Lanoxin</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Cardixin | Lanoxin digoxin | Lanoxin pg</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Digoxina boehringer | Digoxina kern pharma | Lanacordin</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Cardigoxin | Cedoxin | Digoxin medipolar | Digoxin orion | Digoxin star | Lanadix | Lanoxin | Medigoxin medica</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Digoxine Dci | Digoxine nativelle | Hemigoxine | Hemigoxine nativelle | Lanoxin</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Digamex | Digoxin almus | Digoxin boots | Digoxin cox | Digoxin dc | Digoxin kent | Lanoxin | Nativelle digoxin</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Digoxine | Lanoxin</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Lanicor</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Digoxin sopharma | Digoxina kern pharma | Huma-digoxin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Fargoxin | Lanoxin</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Digoxin Zori | Lanoxin | Lanoxin pg</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Cardin | Cardioxin | Caxin | Digitran | Digon | Dixin | Lanoxin | Sangoxin</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Cardioreg | Lanicor | Lanoxin</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin | Lanoxin pg</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Digohan | Digosin | Digoxin Alfresa | Digoxin hd | Digoxin Novartis | Digoxin taiyo | Halfdigoxin | Halfdigoxin KY | Lanoxin</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Digomet | Lanoxin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Digosin | Lanoxin</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin digoxin | Lanoxin pg</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Digoxin bm | Digoxin bp | Digoxin leciva | Digoxine | Dilacor | Dixin | Lanicor | Lanoxin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin Digoxine</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Dilacor | Lanicor | Lanoxin</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Digoxine nativelle</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Digoxina | Gonet | Lanoxin | Lanoxin digoxina | Mapluxin | Valvulan | Vidaxil</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin | Lanoxin pg</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Digoxine | Digoxine eureco pharma | Digoxine gf | Lanoxin | Lanoxin injectie</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Digoxin dak | Digoxin nycomed | Digoxin orifarm | Digoxin tak | Lanoxin</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Digoxin sandoz | Lanoxin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Digoxina</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Digox | Dixin | Inoxin | Lanoxin | Ligoxin</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Digitek | Digox | Lanoxin</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Digoxin bm | Digoxin sopharma</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Digitek | Lanoxin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Digoxina | Lanoxin | Lanoxin MD</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Digoxil | Digoxina fapasa | Digoxina indufar | Digoxina l.ch. | Lanoxin | Metoxal</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin | Lanoxin PG</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Digoxin leciva | Digoxin zentiva</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Digoxin nycomed | Dilacor | Lanicor | Lanoxin</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Lanicor | Lanoxin | Toloxin</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Digoxin astrazeneca | Digoxin Biophausia | Lanoxin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin | Lanoxin Pg Paediatric/Geriatric</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Digoxina kern pharma | Lanicor</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Digoxin leciva</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Digoxin sandoz | Grexin | Lanoxin | Lanoxin pg | Toloxin</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Digoxine | Digoxine nativelle | Digoxine nihfi</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Digoxin assos | Digoxin nativelle</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Digosin | Lanoxin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Lanicor</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Dix</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Digoxil | Digoxina | Lanicor | Lanoxin</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Digoxina | Lanicor</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin | Purgoxin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Digox | Kaydigo | Lanoxin</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Lanoxin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29246961">
<a name="29246961"></a>Alsaied T, Baskar S, Fares M, et al. First-line antiarrhythmic transplacental treatment for fetal tachyarrhythmia: a systematic review and meta-analysis. <i>J Am Heart Assoc</i>. 2017;6(12). pii: e007164. doi: 10.1161/JAHA.117.007164.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/29246961/pubmed" id="29246961" target="_blank">29246961</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi: 10.1002/cpt.377.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
<span class="doi">10.1002/cpt.377</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15339869">
<a name="15339869"></a>Antman EM, Anbe DT, Armstrong PW, et al, "ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction)," <i>Circulation</i>, 2004, 110(9):e82-292.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/15339869/pubmed" id="15339869" target="_blank">15339869</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Aronoff.1">
<a name="Aronoff.1"></a>Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children.</i> 5th ed. Philadelphia, PA: American College of Physicians; 2007:42.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1403399">
<a name="1403399"></a>Azancot-Benisty A, Jacqz-Aigrain E, Guirgis NM, Decrepy A, Oury JF, Blot P. Clinical and pharmacologic study of fetal supraventricular tachyarrhythmias. <i>J Pediatr</i>. 1992;121(4):608-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1403399/pubmed" id="1403399" target="_blank">1403399</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7997427">
<a name="7997427"></a>Bakir M, Bilgiç A. Single daily dose of digoxin for maintenance therapy of infants and children with cardiac disease: is it reliable? <i>Pediatr Cardiol</i>. 1994;15(5):229-232.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7997427/pubmed" id="7997427" target="_blank">7997427</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17159022">
<a name="17159022"></a>Bauman JL, DiDomenico RJ, Viana M, Fitch M. A method of determining the dose of digoxin for heart failure in the modern era. <i>Arch Intern Med</i>. 2006;166(22):2539-2545. doi:10.1001/archinte.166.22.2539<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/17159022/pubmed" id="17159022" target="_blank">17159022</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6349908">
<a name="6349908"></a>Bendayan R, McKenzie MW. Digoxin pharmacokinetics and dosage requirements in pediatric patients. <i>Clin Pharm</i>. 1983;2(3):224-235.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/6349908/pubmed" id="6349908" target="_blank">6349908</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24249760">
<a name="24249760"></a>Benken ST, Lizza BD, Yamout H, Ghossein C. Management of digoxin therapy using pharmacokinetics in a patient undergoing continuous venovenous hemofiltration. <i>Am J Health Syst Pharm</i>. 2013;70(23):2105-2109. doi:10.2146/ajhp130171<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/24249760/pubmed" id="24249760" target="_blank">24249760</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14557344">
<a name="14557344"></a>Blomström-Lundqvist C, Scheinman MM, Aliot EM, et al, “ACC/AHA/ESC Guidelines for the Management of Patients With Supraventricular Arrhythmias--Executive Summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias),” <i>Circulation</i>, 2003, 108(15):1871-909.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/14557344/pubmed" id="14557344" target="_blank">14557344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20844484">
<a name="20844484"></a>Burk O, Brenner SS, Hofmann U, et al. The Impact of Thyroid Disease on the regulation, expression, and function of ABCB1 (MDRa/P-glycoprotein) and consequences for the disposition of digoxin. <i>Clin Pharm Ther</i>. 2010;88(5):685-694.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/20844484/pubmed" id="20844484" target="_blank">20844484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20576808">
<a name="20576808"></a>Chan KE, Lazarus JM, Hakim RM. Digoxin associates with mortality in ESRD. <i>J Am Soc Nephrol</i>. 2010;21(9):1550-1559. doi:10.1681/ASN.2009101047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/20576808/pubmed" id="20576808" target="_blank">20576808</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9165563">
<a name="9165563"></a>Cheng JW, Charland SL, Shaw LM, et al. Is the volume of distribution of digoxin reduced in patients with renal dysfunction? Determining digoxin pharmacokinetics by fluorescence polarization immunoassay. <i>Pharmacotherapy</i>. 1997;17(3):584-590.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/9165563/pubmed" id="9165563" target="_blank">9165563</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21335295">
<a name="21335295"></a>Cheng JW, Rybak I. Use of digoxin for heart failure and atrial fibrillation in elderly patients. <i>Am J Geriatr Pharmacother.</i> 2010;8(5):419-427.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/21335295/pubmed" id="21335295" target="_blank">21335295</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1100180">
<a name="1100180"></a>Croxson MS, Ibbertson HK. Serum digoxin in patients with thyroid disease. <i>Br Med J</i>. 1975;3(5983):566-568. doi:10.1136/bmj.3.5983.566<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1100180/pubmed" id="1100180" target="_blank">1100180</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25164709">
<a name="25164709"></a>DiDomenico RJ, Bress AP, Na-Thalang K, et al. Use of a simplified nomogram to individualize digoxin dosing versus standard dosing practices in patients with heart failure. <i>Pharmacotherapy</i>. 2014;34(11):1121-1131. doi:10.1002/phar.1480<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/25164709/pubmed" id="25164709" target="_blank">25164709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Digitek.1">
<a name="Digitek.1"></a>Digitek (digoxin) tablets [prescribing information]. Morgantown, WV: Mylan Pharmaceuticals Inc; September 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VistaPharm.1">
<a name="VistaPharm.1"></a>Digoxin (digoxin) oral solution [prescribing information]. Largo, FL: VistaPharm, Inc; August 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24763516">
<a name="24763516"></a>Donofrio MT, Moon-Grady AJ, Hornberger LK, et al; American Heart Association Adults With Congenital Heart Disease Joint Committee of the Council on Cardiovascular Disease in the Young and Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and Council on Cardiovascular and Stroke Nursing. Diagnosis and treatment of fetal cardiac disease: a scientific statement from the American Heart Association [published correction appears in <i>Circulation</i>. 2014;129(21):e512]. <i>Circulation</i>. 2014;129(21):2183-2242. doi: 10.1161/01.cir.0000437597.44550.5d.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/24763516/pubmed" id="24763516" target="_blank">24763516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22907424">
<a name="22907424"></a>Escudero C, Carr R, Sanatani S. The medical management of pediatric arrhythmias. <i>Curr Treat Options Cardiovasc Med</i>. 2012;14(5):455-472. doi: 10.1007/s11936-012-0194-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/22907424/pubmed" id="22907424" target="_blank">22907424</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16904574">
<a name="16904574"></a>European Heart Rhythm Association; Heart Rhythm Society, Fuster V, et al, "ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation − Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation)," <i>J Am Coll Cardiol</i>, 2006, 48(4):854-906.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/16904574/pubmed" id="16904574" target="_blank">16904574</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3548521">
<a name="3548521"></a>Falk RH, Knowlton AA, Bernard SA, et al, “Digoxin for Converting Recent-Onset Atrial Fibrillation to Sinus Rhythm, A Randomized, Double-Blinded Trial,” <i>Ann Int Med</i>, 1987, 106(4):503-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/3548521/pubmed" id="3548521" target="_blank">3548521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-762640">
<a name="762640"></a>Finley JP, Waxman MB, Wong PY, Lickrish GM. Digoxin excretion in human milk. <i>J Pediatr</i>. 1979;94(2):339-340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/762640/pubmed" id="762640" target="_blank">762640</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Foote.1">
<a name="Foote.1"></a>Foote E and Dahl N. More drug idiosyncrasies in end-stage renal disease. <i>Seminars in Dialysis</i>. 1998;11(3):167-174.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7094655">
<a name="7094655"></a>Friedman HS, Bonventre MV. Erythromycin-induced digoxin toxicity. <i>Chest</i>. 1982;82(2):202. doi:10.1378/chest.82.2.202-b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7094655/pubmed" id="7094655" target="_blank">7094655</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18221597">
<a name="18221597"></a>Frishman WH, Zeidner J, Naseer N. Diagnosis and Management of Viral Myocarditis. <i>Curr Treat Options Cardiovas Med</i>. 2007;9:450-464.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/18221597/pubmed" id="18221597" target="_blank">18221597</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1834367">
<a name="1834367"></a>Gheorghiade M and Ferguson D. Digoxin. A neurohormonal modulator in heart failure? <i>Circulation</i>. 1991;84(5):2181-2186.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1834367/pubmed" id="1834367" target="_blank">1834367</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Giardina.2018">
<a name="Giardina.2018"></a>Giardina EG. Treatment with digoxin: Initial dosing, monitoring, and dose modification. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 13, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Golightly.1">
<a name="Golightly.1"></a>Golightly LK, Teitelbaum I, Kiser TH, et al, eds. <i>Renal Pharmacotherapy</i>
<i>: Dosage Adjustment of Medications Eliminated by the Kidneys. </i>New York, NY: Springer Science; 2013.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18288078">
<a name="18288078"></a>Hebert MF, Easterling TR, Kirby B, et al. Effects of pregnancy on CYP3A and P-glycoprotein activities as measured by disposition of midazolam and digoxin: a University of Washington specialized center of research study. <i>Clin Pharmacol Ther</i>. 2008;84(2):248-253. doi: 10.1038/clpt.2008.1.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/18288078/pubmed" id="18288078" target="_blank">18288078</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35363499">
<a name="35363499"></a>Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>Circulation</i>. 2022;145(18):e895-e1032. doi:10.1161/CIR.0000000000001063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/35363499/pubmed" id="35363499" target="_blank">35363499</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064600">
<a name="22064600"></a>Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” <i>Circulation</i>, 2011, 124(23):2610-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/22064600/pubmed" id="22064600" target="_blank">22064600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19358937">
<a name="19358937"></a>Hunt SA, Abraham WT, Chin MH, et al, "2009 Focused Update Incorporated Into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation," <i>J Am Coll Cardiol</i>, 2009, 53(15):e1-e90.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/19358937/pubmed" id="19358937" target="_blank">19358937</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>NEJM</i>. 2000;343(2):118-126. doi: 10.1056/NEJM200007133430208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21931080">
<a name="21931080"></a>Jaeggi ET, Carvalho JS, De Groot E, et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. <i>Circulation</i>. 2011;124(16):1747-1754.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/21931080/pubmed" id="21931080" target="_blank">21931080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24682347">
<a name="24682347"></a>January CT, Wann LS, Alpert JS, et al; ACC/AHA Task Force. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society [published online March 28, 2014]. <i>Circulation</i>. doi:10.1161/CIR.0000000000000041.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/24682347/pubmed" id="24682347" target="_blank">24682347</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30703530">
<a name="30703530"></a>January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients with Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>Heart Rhythm</i>. 2019. pii: S1547-5271(19)30037-2. doi: 10.1016/j.hrthm.2019.01.024.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/30703530/pubmed" id="30703530" target="_blank">30703530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10546917">
<a name="10546917"></a>Johne A, Brockmoller J, Bauer S, et al, “Pharmacokinetic Interaction of Digoxin With an Herbal Extract From St John's Wort (<i>Hypericum perforatum</i>),” <i>Clin Pharmacol Ther</i>, 1999, 66(4):338-45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/10546917/pubmed" id="10546917" target="_blank">10546917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4430731">
<a name="4430731"></a>Jusko WJ, Szefler SJ, Goldfarb AL. Pharmacokinetic design of digoxin dosage regimens in relation to renal function. <i>J Clin Pharmacol.</i> 1974;14(10):525-535.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/4430731/pubmed" id="4430731" target="_blank">4430731</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ganz.2018">
<a name="Ganz.2018"></a>Kaplan R. Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 19, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1149366">
<a name="1149366"></a>Koup JR, Jusko WJ, Elwood CM, Kohli RK. Digoxin pharmacokinetics: role of renal failure in dosage regimen design. <i>Clin Pharmacol Ther.</i> 1975;18(1):9-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1149366/pubmed" id="1149366" target="_blank">1149366</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804320">
<a name="8804320"></a>Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. <i>J Pediatr</i>. 1996;129(3):324-338.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/8804320/pubmed" id="8804320" target="_blank">8804320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lanoxin.1">
<a name="Lanoxin.1"></a>Lanoxin (digoxin) tablets [prescribing information]. Research Triangle Park, NC: Glaxosmithkline; February 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lanoxin.2">
<a name="Lanoxin.2"></a>Lanoxin (digoxin) injection [prescribing information]. Research Triangle Park, NC: Glaxosmithkline; October 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Lanoxin.3">
<a name="Lanoxin.3"></a>Lanoxin (digoxin) tablets [product monograph]. Montreal, Quebec, Canada: Pharmascience; January 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11114547">
<a name="11114547"></a>Latifi S, Lidsky K, Blumer JL. Pharmacology of inotropic agents in infants and children. <i>Prog Pediatr Cardiol</i>. 2000;12(1):57-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/11114547/pubmed" id="11114547" target="_blank">11114547</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Levine.1">
<a name="Levine.1"></a>Levine JC, Alexander ME. Fetal arrhythmias. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 5, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25371716">
<a name="25371716"></a>Li X, Ao X, Liu Q, et al. Intermittent low-dose digoxin may be effective and safe in patients with chronic heart failure undergoing maintenance hemodialysis. <i>Exp Ther Med</i>. 2014;8(6):1689-1694. doi:10.3892/etm.2014.2013<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/25371716/pubmed" id="25371716" target="_blank">25371716</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27239633">
<a name="27239633"></a>Limon G, Ersoy G, Oray NC, Bayram B, Limon O. Retrospective evaluation of patients with elevated digoxin levels at an emergency department. <i>Turk J Emerg Med</i>. 2016;16(1):17-21. doi:10.1016/j.tjem.2015.10.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/27239633/pubmed" id="27239633" target="_blank">27239633</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29519345">
<a name="29519345"></a>Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. <i>J Am Coll Cardiol</i>. 2018;71(10):1063-1074.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/29519345/pubmed" id="29519345" target="_blank">29519345</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6617713">
<a name="6617713"></a>Luxford AM, Kellaway GS. Pharmacokinetics of digoxin in pregnancy. <i>Eur J Clin Pharmacol</i>. 1983;25(1):117-121.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/6617713/pubmed" id="6617713" target="_blank">6617713</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11207409">
<a name="11207409"></a>Ma G, Brady WJ, Pollack M, Chan TC. Electrocardiographic manifestations: digitalis toxicity. <i>J Emerg Med</i>. 2001;20(2):145-152. doi:10.1016/s0736-4679(00)00312-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/11207409/pubmed" id="11207409" target="_blank">11207409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2239670">
<a name="2239670"></a>Mahdyoon H, Battilana G, Rosman H, Goldstein S, Gheorghiade M. The evolving pattern of digoxin intoxication: observations at a large urban hospital from 1980 to 1988. <i>Am Heart J</i>. 1990;120(5):1189-1194. doi:10.1016/0002-8703(90)90135-k<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/2239670/pubmed" id="2239670" target="_blank">2239670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8201728">
<a name="8201728"></a>Martin SJ, Shah D. Cutaneous hypersensitivity reaction to digoxin. <i>JAMA</i>. 1994;271(24):1905.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/8201728/pubmed" id="8201728" target="_blank">8201728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631514">
<a name="28631514"></a>Martin-Suarez A, Sanchez-Hernandez JG, Medina-Barajas F, et al. Pharmacokinetics and dosing requirements of digoxin in pregnant women treated for fetal supraventricular tachycardia. <i>Expert Rev Clin Pharmacol</i>. 2017;10(8):911-917. doi: 10.1080/17512433.2017.1344096.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/28631514/pubmed" id="28631514" target="_blank">28631514</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10614837">
<a name="10614837"></a>Matsumori A, Igata H, Ono K, et al. High doses of digitalis increase the myocardial production of proinflammatory cytokines and worsen myocardial injury in viral myocarditis: a possible mechanism of digitalis toxicity. <i>Jpn Circ J</i>. 1999;63:934-990.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/10614837/pubmed" id="10614837" target="_blank">10614837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28851790">
<a name="28851790"></a>Miyoshi T, Maeno Y, Sago H, et al; Japan Fetal Arrhythmia Group. Antenatal antiarrhythmic treatment for fetal tachyarrhythmias: a study protocol for a prospective multicentre trial. <i>BMJ Open</i>. 2017;7(8):e016597. doi: 10.1136/bmjopen-2017-016597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/28851790/pubmed" id="28851790" target="_blank">28851790</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29208503">
<a name="29208503"></a>Moatassim S, Touleimat S, Hazelzet T, et al. Maternal complications induced by digoxin treatment of fetal tachycardia: A retrospective series of 18 cases. <i>J Gynecol Obstet Hum Reprod</i>. 2018;47(2):35-38. doi: 10.1016/j.jogoh.2017.11.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/29208503/pubmed" id="29208503" target="_blank">29208503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3052985">
<a name="3052985"></a>Mooradian AD. Digitalis. An update of clinical pharmacokinetics, therapeutic monitoring techniques and treatment recommendations. <i>Clin Pharmacokinet</i>. 1988;15(3):165-179. doi:10.2165/00003088-198815030-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/3052985/pubmed" id="3052985" target="_blank">3052985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20956224">
<a name="20956224"></a>Neumar RW, Otto CW, Link MS, et al. Part 8: adult advanced cardiovascular life support: 2010 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care [published corrections appear in <i>Circulation</i>. 2011;123(6):e236; <i>Circulation</i>. 2013;128(25):e480]. <i>Circulation</i>. 2010;122(18)(suppl 3):S729-S767.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/20956224/pubmed" id="20956224" target="_blank">20956224</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3325214">
<a name="3325214"></a>O'Connor P, Feely J. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. <i>Clin Pharmacokinet</i>. 1987;13(6):345-364. doi:10.2165/00003088-198713060-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/3325214/pubmed" id="3325214" target="_blank">3325214</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7461014">
<a name="7461014"></a>Ohnhaus EE, Lenzinger HR, Galeazzi RL. Comparison of two different loading doses of digoxin in severe renal impairment. <i>Eur J Clin Pharmacol</i>. 1980;18(6):467-472. doi:10.1007/BF00874657<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7461014/pubmed" id="7461014" target="_blank">7461014</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33229116">
<a name="33229116"></a>Ommen SR, Mital S, Burke MA, et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. <i>J Am Coll Cardiol</i>. 2020;76(25):e159-e240. doi:10.1016/j.jacc.2020.08.045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/33229116/pubmed" id="33229116" target="_blank">33229116</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7560629">
<a name="7560629"></a>O'Sullivan JJ, Gardiner HM, Wren C. Digoxin or flecainide for prophylaxis of supraventricular tachycardia in infants? <i>J Am Coll Cardiol</i>. 1995;26(4):991-994.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7560629/pubmed" id="7560629" target="_blank">7560629</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8505940">
<a name="8505940"></a>Packer M, Gheorghiade M, Young JB, et al, “Withdrawal of Digoxin From Patients With Chronic Heart Failure Treated With Angiotensin-converting Enzyme Inhibitors, RADIANCE Study,” <i>N Engl J Med</i>, 1993, 329(1):1-77.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/8505940/pubmed" id="8505940" target="_blank">8505940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26409259">
<a name="26409259"></a>Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society [published correction appears in <i>J Am Coll Cardiol. </i>2016;68:25):2922-2923]. <i>J Am Coll Cardiol</i>. 2016;67(13):e27-e115. doi: 10.1016/j.jacc.2015.08.856.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/26409259/pubmed" id="26409259" target="_blank">26409259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8989479">
<a name="8989479"></a>Parilla BV, Strasburger JF, Socol ML. Fetal supraventricular tachycardia complicated by hydrops fetalis: a role for direct fetal intramuscular therapy. <i>Am J Perinatol</i>. 1996;13(8):483-486.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/8989479/pubmed" id="8989479" target="_blank">8989479</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3012054">
<a name="3012054"></a>Park MK. Use of digoxin in infants and children, with specific emphasis on dosage. <i>J Pediatr</i>. 1986;108(6):871-877.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/3012054/pubmed" id="3012054" target="_blank">3012054</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27041802">
<a name="27041802"></a>Pincus M. Management of digoxin toxicity. <i>Aust Prescr</i>. 2016;39(1):18-20. doi:10.18773/austprescr.2016.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/27041802/pubmed" id="27041802" target="_blank">27041802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7215418">
<a name="7215418"></a>Pirovino M, Ohnhaus EE, von Felten A. Digoxin-associated thrombocytopaenia. <i>Eur J Clin Pharmacol</i>. 1981;19(3):205-207. doi:10.1007/BF00561950<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7215418/pubmed" id="7215418" target="_blank">7215418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer’s labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30165544">
<a name="30165544"></a>Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al; ESC Scientific Document Group. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. <i>Eur Heart J</i>. 2018;39(34):3165-3241. doi: 10.1093/eurheartj/ehy340.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/30165544/pubmed" id="30165544" target="_blank">30165544</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7075628">
<a name="7075628"></a>Reinhardt D, Richter O, Genz T et al. Kinetics of the transplacental passage of digoxin from breast feeding mothers to their infants. <i>Eur J Pediatr</i>. 1982;138:49-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7075628/pubmed" id="7075628" target="_blank">7075628</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Ross.1">
<a name="Ross.1"></a>Ross RD, "Medical Management of Chronic Heart Failure in Children," <i>Am J Cardiovasc Drugs</i>, 2001, 1(1):37-44.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22962431">
<a name="22962431"></a>Sanatani S, Potts JE, Reed JH, et al. The study of antiarrhythmic medications in infancy (SAMIS): a multicenter, randomized controlled trial comparing the efficacy and safety of digoxin versus propranolol for prophylaxis of supraventricular tachycardia in infants. <i>Circ Arrhythm Electrophysiol</i>. 2012;5(5):984-991.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/22962431/pubmed" id="22962431" target="_blank">22962431</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17000935">
<a name="17000935"></a>Shah KB, Inoue Y, Mehra MR. Amyloidosis and the heart: a comprehensive review. <i>Arch Intern Med</i>. 2006;166(17):1805-1813. doi:10.1001/archinte.166.17.1805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/17000935/pubmed" id="17000935" target="_blank">17000935</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19188870">
<a name="19188870"></a>Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/19188870/pubmed" id="19188870" target="_blank">19188870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10078084">
<a name="10078084"></a>Simpson JM, Sharland GK. Fetal tachycardias: Management and outcome of 127 consecutive cases. <i>Heart</i>. 1998;79:576-581.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/10078084/pubmed" id="10078084" target="_blank">10078084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19487941">
<a name="19487941"></a>Siu CW, Lau CP, Lee WL, et al, “Intravenous Diltiazem is Superior to Intravenous Amiodarone or Digoxin for Achieving Ventricular Rate Control in Patients With Acute Uncomplicated Atrial Fibrillation,” <i>Crit Care Med</i>, 2009, 37(7):2174-9.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/19487941/pubmed" id="19487941" target="_blank">19487941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22433576">
<a name="22433576"></a>Skanes AC, Healey JS, Cairns JA, et al, “Focused 2012 Update of the Canadian Cardiovascular Society Atrial Fibrillation Guidelines: Recommendations for Stroke Prevention and Rate/Rhythm Control,” <i>Can J Cardiol</i>, 2012, 28(2):125-36.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/22433576/pubmed" id="22433576" target="_blank">22433576</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32929996">
<a name="32929996"></a>Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. <i>Circulation</i>. 2020;142(15):e214-e233. doi:10.1161/CIR.0000000000000905<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/32929996/pubmed" id="32929996" target="_blank">32929996</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25939649">
<a name="25939649"></a>Vamos M, Erath JW, Hohnloser SH. Digoxin-associated mortality: a systematic review and meta-analysis of the literature. <i>Eur Heart J</i>. 2015;36(28):1831-1838.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/25939649/pubmed" id="25939649" target="_blank">25939649</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7930263">
<a name="7930263"></a>van Engelen AD, Weijtens O, Brenner JI, et al. Management outcome and follow-up of fetal tachycardia. <i>J Am Coll Cardiol</i>. 1994;24(5):1371-1375.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/7930263/pubmed" id="7930263" target="_blank">7930263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1997015">
<a name="1997015"></a>Wofford JL, Ettinger WH. Risk factors and manifestations of digoxin toxicity in the elderly. <i>Am J Emerg Med</i>. 1991;9(2 Suppl 1):11-34. doi:10.1016/0735-6757(91)90161-c<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/1997015/pubmed" id="1997015" target="_blank">1997015</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-WHO.1">
<a name="WHO.1"></a>World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the eleventh WHO model list of essential drugs. 2002. Available at http://www.who.int/maternal_child_adolescent/documents/55732/en/.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17555487">
<a name="17555487"></a>Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/digoxin-drug-information/abstract-text/17555487/pubmed" id="17555487" target="_blank">17555487</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9360 Version 610.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
